Fig. 2

Patients with increased ASS1 expression in HCC have a more favorable prognosis a ASS1 mRNA expression levels and b Expression of ASS1 in hepatocytes; Fa2N-4, miha., Caucasian-derived HCC cells; Hep3B, Huh6, HepG2, and PLC/PRF/5, and Korean-derived HCC cells; SNU449, SNU475, SNU398, and SNU898. c ASS1 mRNA expression levels in tumor spheroids from eight Korean patient-derived HCC cell lines, six Asian patient-derived HCC cell lines (SNU449, SNU475, SNU878, Huh7, AMC-H1 and AMC-H2), three Caucasian patient-derived HCC cell lines (Hep3B, Huh6 and SKhep-1), and normal hepatocyte (Fa2N-4). d ASS1 expression in adjacent peritumoral tissues (N) and tumor tissues (T) from HCC patient samples by western blot analysis. e 10-year overall survival rates of patients with high vs. low expression of ASS1. (N = peritumoral tissues, T = tumor tissues) ^*P < 0.05 and ^***P < 0.001 compared to control group